🇺🇸 FDA
Patent

US 12186324

Imidazopiperazine inhibitors of transcription activating proteins

granted A61KA61K31/4985A61K31/5377

Quick answer

US patent 12186324 (Imidazopiperazine inhibitors of transcription activating proteins) held by The Board of Regents of the University of Texas System expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Texas System
Grant date
Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
26
CPC classes
A61K, A61K31/4985, A61K31/5377